Treatment of ALK Positive Non-small Cell Lung Cancer with Alectinib:
A Case Report and Literature Review.
10.3779/j.issn.1009-3419.2021.101.34
- Author:
Haixiang YANG
1
;
Wei ZHU
1
Author Information
1. Department of Oncology, Baotou Central Hospital, Baotou 014040, China.
- Publication Type:Review
- Keywords:
Alectinib;
Anaplastic lymphoma kinase;
Lung neoplasms;
Side effects
- MeSH:
Anaplastic Lymphoma Kinase/genetics*;
Antineoplastic Agents/therapeutic use*;
Carbazoles/therapeutic use*;
Carcinoma, Non-Small-Cell Lung/secondary*;
Humans;
Lung Neoplasms/pathology*;
Mutation;
Piperidines/therapeutic use*;
Pleural Neoplasms/secondary*;
Protein Kinase Inhibitors/therapeutic use*;
Retrospective Studies;
Tomography, X-Ray Computed
- From:
Chinese Journal of Lung Cancer
2021;24(9):673-676
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is a malignant tumor with high incidence rate and mortality rate in China and even the whole world, of which non-small cell lung cancer accounts for about 80%. Anaplastic lymphoma kinase (ALK) gene mutation accounts for about 5%. Alectinib, ALK-tyrosine kinase inhibitor (ALK-TKI), has great performance in clinical. The early detection and treatment of adverse drug reactions can greatly improve clinical benefits. This paper reports a patient of ALK positive non-small cell lung cancer was admited to Baotou Central Hospital in April 2020. The diagnosis and treatment was retrospectively analyzed, and the literature was reviewed.
.
